Increased expression of Eps15 homology domain 1 is associated with poor prognosis in resected small cell lung cancer

Journal of Cancer

Volumn 6, Issue 10, 2015, Pages 990-995

  Meng, Qingwei ^a   Sun, Weiling ^a   Li, Man ^a   Zhao, Yanbin ^a   Chen, Xuesong ^a   Sun, Lichun ^a   Cai, Li ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Disease free survival; Eps15 homology domain 1; Immunohistochemistry; Small cell lung cancer; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15; EPS15 HOMOLOGY DOMAIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF RADIOTHERAPY; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; SMOKING; TUMOR VOLUME;

EID: 84947736992     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11650     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61: 69-90. doi:10.3322/caac.20107.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. 2013; 63: 11-30. doi:10.3322/caac.21166.
3. Oberg K, Hellman P, Kwekkeboom D, Jelic S, Group EGW. Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2010; 21 Suppl 5: v220-2. doi:10.1093/annonc/mdq191.
4. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24: 4539-44. doi:10.1200/JCO.2005.04.4859.
5. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Bethesda: National Cancer Institute; 2009.
6. 1088366Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, et al. Small cell lung cancer. Journal of the National Comprehensive Cancer Network: JNCCN. 2013; 11: 78-98.
7. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. British journal of cancer. 2000; 83: 8-15. doi:10.1054/bjoc.2000.1164.
8. Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematology/oncology clinics of North America. 2004; 18: 309-22. doi:10.1016/j.hoc.2003.12.008.
9. Murray N, Turrisi AT, 3rd. A review of first-line treatment for small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2006; 1: 270-8.
10. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology. 2008; 22: 1486-92.
11. Davies AM, Lara PN, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematology/oncology clinics of North America. 2004; 18: 373-85. doi:10.1016/j.hoc.2003.12.012.
12. Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, et al. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Molecular cancer therapeutics. 2012; 11: 604-15. doi:10.1158/1535-7163.MCT-11-0599.
13. Wangpaichitr M, Wu C, You M, Maher JC, Dinh V, Feun LG, et al. N', N'-Dimethyl-N', N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers. 2009; 1: 23-38. doi:10.3390/cancers1010023.
14. Schwab M. Amplification of oncogenes in human cancer cells. BioEssays: news and reviews in molecular, cellular and developmental biology. 1998; 20: 473-9. doi:10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N.
15. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer letters. 1995; 90: 43-50.
16. Gollin SM. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head & neck. 2001; 23: 238-53.
17. Xu J, Tyan T, Cedrone E, Savaraj N, Wang N. Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes, chromosomes & cancer. 1996; 17: 172-8. doi:10.1002/(SICI)1098-2264(199611)17:3<172::AID-GCC5>3.0.CO;2-1.
18. Sato M, Sato K, Liou W, Pant S, Harada A, Grant BD. Regulation of endocytic recycling by C. elegans Rab35 and its regulator RME-4, a coated-pit protein. The EMBO journal. 2008; 27: 1183-96. doi:10.1038/emboj.2008.54.
19. Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends in cell biology. 2011; 21: 122-31. doi:10.1016/j.tcb.2010.10.003.
20. Jovic M, Naslavsky N, Rapaport D, Horowitz M, Caplan S. EHD1 regulates beta1 integrin endosomal transport: effects on focal adhesions, cell spreading and migration. Journal of cell science. 2007; 120: 802-14. doi:10.1242/jcs.03383.
21. Caswell PT, Norman JC. Integrin trafficking and the control of cell migration. Traffic. 2006; 7: 14-21. doi:10.1111/j.1600-0854.2005.00362.x.
22. Dunphy JL, Moravec R, Ly K, Lasell TK, Melancon P, Casanova JE. The Arf6 GEF GEP100/BRAG2 regulates cell adhesion by controlling endocytosis of beta1 integrins. Current biology: CB. 2006; 16: 315-20. doi:10.1016/j.cub.2005.12.032.
23. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Current biology: CB. 2001; 11: 1392-402.
24. Pal NR, Aguan K, Sharma A, Amari S. Discovering biomarkers from gene expression data for predicting cancer subgroups using neural networks and relational fuzzy clustering. BMC bioinformatics. 2007; 8: 5. doi:10.1186/1471-2105-8-5.
25. Kamens AJ, Eisert RJ, Corlin T, Baleja JD, Kritzer JA. Structured Cyclic Peptides That Bind the EH Domain of EHD1. Biochemistry. 2014; 53: 4758-60. doi:10.1021/bi500744q.
26. Gao Y, Wang Y, Sun L, Meng Q, Cai L, Dong X. Expression of TGFbeta-1 and EHD1 correlated with survival of non-small cell Lung cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi:10.1007/s13277-014-2164-x.
27. Lu H, Meng Q, Wen Y, Hu J, Zhao Y, Cai L. IncreasedEHD1 in non-small cell lung cancer predicts poor survival. Thoracic Cancer. 2013; 4: 422-32.
28. Wu ZZ, Lu HP, Chao CC. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochemical pharmacology. 2010; 80: 262-76. doi:10.1016/j.bcp.2010.03.029.
29. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007; 110: 3015-27. doi:10.1182/blood-2006-12-061507.
30. Cai B, Giridharan SS, Zhang J, Saxena S, Bahl K, Schmidt JA, et al. Differential roles of C-terminal Eps15 homology domain proteins as vesiculators and tubulators of recycling endosomes. The Journal of biological chemistry. 2013; 288: 30172-80. doi:10.1074/jbc.M113.488627.
31. Lin SX, Grant B, Hirsh D, Maxfield FR. Rme-1 regulates the distribution and function of the endocytic recycling compartment in mammalian cells. Nature cell biology. 2001; 3: 567-72. doi:10.1038/35078543.
32. Naslavsky N, Boehm M, Backlund PS, Jr., Caplan S. Rabenosyn-5 and EHD1 interact and sequentially regulate protein recycling to the plasma membrane. Molecular biology of the cell. 2004; 15: 2410-22. doi:10.1091/mbc.E03-10-0733.
33. Caplan S, Naslavsky N, Hartnell LM, Lodge R, Polishchuk RS, Donaldson JG, et al. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. The EMBO journal. 2002; 21: 2557-67. doi:10.1093/emboj/21.11.2557.
34. Picciano JA, Ameen N, Grant BD, Bradbury NA. Rme-1 regulates the recycling of the cystic fibrosis transmembrane conductance regulator. American journal of physiology Cell physiology. 2003; 285: C1009-18. doi:10.1152/ajpcell.00140.2003.
35. Soldati T, Schliwa M. Powering membrane traffic in endocytosis and recycling. Nature reviews Molecular cell biology. 2006; 7: 897-908. doi:10.1038/nrm2060.
36. Naslavsky N, Caplan S. C-terminal EH-domain-containing proteins: consensus for a role in endocytic trafficking, EH? Journal of cell science. 2005; 118: 4093-101. doi:10.1242/jcs.02595.
37. Dealy CN, Kosher RA. IGF-I and insulin in the acquisition of limb-forming ability by the embryonic lateral plate. Developmental biology. 1996; 177: 291-9. doi:10.1006/dbio.1996.0163.
38. Lok F, Owens JA, Mundy L, Robinson JS, Owens PC. Insulin-like growth factor I promotes growth selectively in fetal sheep in late gestation. The American journal of physiology. 1996; 270: R1148-55.
39. Guilherme A, Soriano NA, Furcinitti PS, Czech MP. Role of EHD1 and EHBP1 in perinuclear sorting and insulin-regulated GLUT4 recycling in 3T3-L1 adipocytes. The Journal of biological chemistry. 2004; 279: 40062-75. doi:10.1074/jbc.M401918200.
40. Burney S, Irfan K, Saif MW, Masud F. Diabetes and pancreatic cancer. JOP: Journal of the pancreas. 2014; 15: 319-21. doi:10.6092/1590-8577/2680.
41. Benabbou N, Mirshahi P, Bordu C, Faussat AM, Tang R, Therwath A, et al. A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. International journal of oncology. 2014. doi:10.3892/ijo.2014.2569.
42. Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma non-alcoholic fatty liver disease? World journal of gastroenterology: WJG. 2014; 20: 9217-28. doi:10.3748/wjg.v20.i28.9217.
43. Sarkissyan S, Sarkissyan M, Wu Y, Cardenas J, Koeffler HP, Vadgama JV. IGF-1 Regulates Cyr61 Induced Breast Cancer Cell Proliferation and Invasion. PloS one. 2014; 9: e103534. doi:10.1371/journal.pone.0103534.
44. Zheng X, Xu M, Fang Q. Role of AMPK alpha in Skeletal Muscle Glycometabolism Regulation and Adaptation in relation to Sepsis. BioMed research international. 2014; 2014: 390760. doi:10.1155/2014/390760.
45. Fincham VJ, Frame MC. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. The EMBO journal. 1998; 17: 81-92. doi:10.1093/emboj/17.1.81.
46. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. The oncologist. 2009; 14: 667-78. doi:10.1634/theoncologist.2009-0009.
47. Heidemann F, Schildt A, Schmid K, Bruns OT, Riecken K, Jung C, et al. Selectins mediate small cell lung cancer systemic metastasis. PloS one. 2014; 9: e92327. doi:10.1371/journal.pone.0092327.
48. Zhang F, Wang Y, Xu M, Dong H, Liu N, Zhou J, et al. MGr1-Ag promotes invasion and bone metastasis of small-cell lung cancer in vitro and in vivo. Oncology reports. 2013; 29: 2283-90. doi:10.3892/or.2013.2396.
49. Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer. 2003; 22: 147-65.